Cell mediated immune response assay with enhanced sensitivity
AssigneeCellestis Limited
InventorJeff Boyle
Life of this patent
Estimating the term…
Abstract
This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
Claims23
A method for measuring cell-mediated immune response activity in a subject, said method comprising contacting a sample comprising lymphocytes from the subject with at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater, which peptides encompass all or part of a protein antigen;
- and measuring presence or elevation in level of an immune effector molecule from immune cells, wherein the presence or level of the immune effector molecule is indicative of a level of cell-mediated responsiveness of the subject.
The method of claim 11 wherein the cytokine is IFN-γ.
A method of allowing a user to determine cell-mediated immunoresponsiveness status of a subject, the method comprising:
- (a) receiving subject data that are provided as levels or concentrations of an immune effector molecule in the subject which, relative to the level or concentration of the immune effector molecule in a control subject, provide a correlation to a state of cell-mediated immunoresponsiveness from the user via a communications network, the immune effector molecule being measured after exposure of lymphocytes from the subject to at least two sets of peptides, a first set comprising at least one peptide of from about 7 to 14 amino acid residues in length and a second set comprising at least one peptide of from 16 amino acid residues or greater, which peptides encompass all or part of a protein antigen;
- (b) processing the subject data via univariate or multivariate analysis to provide an immunoresponsiveness value;
- (c) determining the cell-mediated immunoresponsiveness status of the subject by comparing the immunoresponsiveness value of (b) to one or more predetermined values;
- and
- (d) transferring an indication of the cell-mediated immunoresponsiveness status of the subject to the user via the communications network.
Dependencies are inferred from the claim text.